These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 19610651)

  • 1. Small molecule chloropyramine hydrochloride (C4) targets the binding site of focal adhesion kinase and vascular endothelial growth factor receptor 3 and suppresses breast cancer growth in vivo.
    Kurenova EV; Hunt DL; He D; Magis AT; Ostrov DA; Cance WG
    J Med Chem; 2009 Aug; 52(15):4716-24. PubMed ID: 19610651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The FAK scaffold inhibitor C4 disrupts FAK-VEGFR-3 signaling and inhibits pancreatic cancer growth.
    Kurenova E; Liao J; He DH; Hunt D; Yemma M; Bshara W; Seshadri M; Cance WG
    Oncotarget; 2013 Oct; 4(10):1632-46. PubMed ID: 24142503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A FAK scaffold inhibitor disrupts FAK and VEGFR-3 signaling and blocks melanoma growth by targeting both tumor and endothelial cells.
    Kurenova E; Ucar D; Liao J; Yemma M; Gogate P; Bshara W; Sunar U; Seshadri M; Hochwald SN; Cance WG
    Cell Cycle; 2014; 13(16):2542-53. PubMed ID: 25486195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of FAK and VEGFR-3 binding decreases tumorigenicity in neuroblastoma.
    Stewart JE; Ma X; Megison M; Nabers H; Cance WG; Kurenova EV; Beierle EA
    Mol Carcinog; 2015 Jan; 54(1):9-23. PubMed ID: 23868727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis, and biological evaluation of novel FAK scaffold inhibitors targeting the FAK-VEGFR3 protein-protein interaction.
    Gogate PN; Ethirajan M; Kurenova EV; Magis AT; Pandey RK; Cance WG
    Eur J Med Chem; 2014 Jun; 80():154-166. PubMed ID: 24780592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vascular endothelial growth factor receptor-3 and focal adhesion kinase bind and suppress apoptosis in breast cancer cells.
    Garces CA; Kurenova EV; Golubovskaya VM; Cance WG
    Cancer Res; 2006 Feb; 66(3):1446-54. PubMed ID: 16452200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of focal adhesion kinase inhibitors in cancer therapy.
    Ma WW
    Anticancer Agents Med Chem; 2011 Sep; 11(7):638-42. PubMed ID: 21787276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A small-molecule inhibitor, 5'-O-tritylthymidine, targets FAK and Mdm-2 interaction, and blocks breast and colon tumorigenesis in vivo.
    Golubovskaya VM; Palma NL; Zheng M; Ho B; Magis A; Ostrov D; Cance WG
    Anticancer Agents Med Chem; 2013 May; 13(4):532-45. PubMed ID: 22292771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphorylation of RACK1 on tyrosine 52 by c-Abl is required for insulin-like growth factor I-mediated regulation of focal adhesion kinase.
    Kiely PA; Baillie GS; Barrett R; Buckley DA; Adams DR; Houslay MD; O'Connor R
    J Biol Chem; 2009 Jul; 284(30):20263-74. PubMed ID: 19423701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic targeting of the focal adhesion complex prevents oncogenic TGF-beta signaling and metastasis.
    Wendt MK; Schiemann WP
    Breast Cancer Res; 2009; 11(5):R68. PubMed ID: 19740433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of the focal adhesion kinase and vascular endothelial growth factor receptor-3 interaction leads to decreased survival in human neuroblastoma cell lines.
    Beierle EA; Ma X; Stewart JE; Megison M; Cance WG; Kurenova EV
    Mol Carcinog; 2014 Mar; 53(3):230-42. PubMed ID: 23065847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral delivery of PND-1186 FAK inhibitor decreases tumor growth and spontaneous breast to lung metastasis in pre-clinical models.
    Walsh C; Tanjoni I; Uryu S; Tomar A; Nam JO; Luo H; Phillips A; Patel N; Kwok C; McMahon G; Stupack DG; Schlaepfer DD
    Cancer Biol Ther; 2010 May; 9(10):778-90. PubMed ID: 20234193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibiting the interaction of cMET and IGF-1R with FAK effectively reduces growth of pancreatic cancer cells in vitro and in vivo.
    Ucar DA; Magis AT; He DH; Lawrence NJ; Sebti SM; Kurenova E; Zajac-Kaye M; Zhang J; Hochwald SN
    Anticancer Agents Med Chem; 2013 May; 13(4):595-602. PubMed ID: 23272972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The discovery of new and more potent chloropyramine (C4) analogues for the potential treatment of invasive breast cancer.
    Kandil S; Prencipe F; Jones S; Hiscox S; Westwell AD
    Chem Biol Drug Des; 2018 Jan; 91(1):314-321. PubMed ID: 28816016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A small molecule inhibitor, 1,2,4,5-benzenetetraamine tetrahydrochloride, targeting the y397 site of focal adhesion kinase decreases tumor growth.
    Golubovskaya VM; Nyberg C; Zheng M; Kweh F; Magis A; Ostrov D; Cance WG
    J Med Chem; 2008 Dec; 51(23):7405-16. PubMed ID: 18989950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of novel chloropyramine-cinnamic acid hybrids as potential FAK inhibitors for intervention of metastatic triple-negative breast cancer.
    Yang F; Xu K; Zhang S; Zhang J; Qiu Y; Luo J; Tan G; Zou Z; Wang W; Kang F
    Bioorg Med Chem; 2022 Jul; 66():116809. PubMed ID: 35569251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-metastatic action of FAK inhibitor OXA-11 in combination with VEGFR-2 signaling blockade in pancreatic neuroendocrine tumors.
    Moen I; Gebre M; Alonso-Camino V; Chen D; Epstein D; McDonald DM
    Clin Exp Metastasis; 2015 Dec; 32(8):799-817. PubMed ID: 26445848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FAK activity protects nucleostemin in facilitating breast cancer spheroid and tumor growth.
    Tancioni I; Miller NL; Uryu S; Lawson C; Jean C; Chen XL; Kleinschmidt EG; Schlaepfer DD
    Breast Cancer Res; 2015 Mar; 17():47. PubMed ID: 25880415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting focal adhesion kinase with dominant-negative FRNK or Hsp90 inhibitor 17-DMAG suppresses tumor growth and metastasis of SiHa cervical xenografts.
    Schwock J; Dhani N; Cao MP; Zheng J; Clarkson R; Radulovich N; Navab R; Horn LC; Hedley DW
    Cancer Res; 2009 Jun; 69(11):4750-9. PubMed ID: 19458065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cellular characterization of a novel focal adhesion kinase inhibitor.
    Slack-Davis JK; Martin KH; Tilghman RW; Iwanicki M; Ung EJ; Autry C; Luzzio MJ; Cooper B; Kath JC; Roberts WG; Parsons JT
    J Biol Chem; 2007 May; 282(20):14845-52. PubMed ID: 17395594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.